ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
Renal Insufficiency
IGA Glomerulonephritis
Renal Cell Carcinoma
Diabetes Mellitus

Kidney Disease trials near Warszawa, Mazowieckie, POL:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Warszawa, Poland and 17 other locations

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. W...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Placebo (Semaglutide)
Drug: Semaglutide

Phase 3

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 32 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Zibotentan/Dapagliflozin
Drug: Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Warszawa, Poland and 324 other locations

Locations recently updated

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling
Chronic Kidney Disease
Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 109 other locations

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

Phase 2

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 105 other locations

Locations recently updated

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Warszawa, Poland and 176 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Warszawa, Poland and 141 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Placebo
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Warszawa, Poland and 147 other locations

(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab C)

Phase 3

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 944 other locations

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This...

Enrolling
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Dapagliflozin in combination with placebo

Phase 3

AstraZeneca
AstraZeneca

Warszawa, Poland and 568 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems